Depreciation of Vivos Therapeutics, Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Vivos Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Vivos Therapeutics, Inc. Depreciation for the quarter ending 30 Sep 2025 was $400,000, a 300% increase year-over-year.
  • Vivos Therapeutics, Inc. Depreciation for the twelve months ending 30 Sep 2025 was $1,200,000, a 140% increase year-over-year.
  • Vivos Therapeutics, Inc. annual Depreciation for 2024 was $600,000, unchanged from 2023.
  • Vivos Therapeutics, Inc. annual Depreciation for 2023 was $600,000, unchanged from 2022.
  • Vivos Therapeutics, Inc. annual Depreciation for 2022 was $600,000, a 50% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Vivos Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,200,000 $400,000 +$300,000 +300% 01 Jul 2025 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $900,000 $300,000 +$200,000 +200% 01 Apr 2025 30 Jun 2025 10-Q 19 Aug 2025 2025 Q2
Q1 2025 $700,000 $200,000 +$100,000 +100% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $600,000 $300,000 +$100,000 +50% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $500,000 $100,000 $0 0% 01 Jul 2024 30 Sep 2024 10-Q 19 Nov 2025 2025 Q3
Q2 2024 $500,000 $100,000 $0 0% 01 Apr 2024 30 Jun 2024 10-Q 19 Aug 2025 2025 Q2
Q1 2024 $500,000 $100,000 -$100,000 -50% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $600,000 $200,000 +$200,000 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $400,000 $100,000 -$100,000 -50% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $500,000 $100,000 -$100,000 -50% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $600,000 $200,000 $0 0% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $600,000 $0 -$119,403 -100% 01 Oct 2022 31 Dec 2022 10-K/A 30 Jul 2024 2023 FY
Q3 2022 $719,403 $200,000 +$100,000 +100% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $619,403 $200,000 +$119,403 +148% 01 Apr 2022 30 Jun 2022 10-Q 20 Dec 2022 2022 Q2
Q1 2022 $500,000 $200,000 +$100,000 +100% 01 Jan 2022 31 Mar 2022 10-Q/A 25 Nov 2022 2022 Q1
Q4 2021 $400,000 $119,403 +$133,675 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $266,325 $100,000 -$62,180 -38% 01 Jul 2021 30 Sep 2021 10-Q 20 Dec 2022 2022 Q3
Q2 2021 $328,505 $80,597 +$4,716 +6.2% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $323,789 $100,000 +$23,789 +31% 01 Jan 2021 31 Mar 2021 10-Q/A 25 Nov 2022 2022 Q1
Q4 2020 $300,000 $14,272 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $162,180 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $75,881 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $76,211 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

Vivos Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $600,000 $0 0% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $600,000 $0 0% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $600,000 +$200,000 +50% 01 Jan 2022 31 Dec 2022 10-K/A 30 Jul 2024 2023 FY
2021 $400,000 +$100,000 +33% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $300,000 -$26,849 -8.2% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $326,849 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.